Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma

키워드

참고문헌 (73)

1. Ferlay J, "Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
2. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
3. Velázquez RF, "Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis", Hepatology, 37, pp.520~527 (2003)
4. Fattovich G, "Hepatocellular carcinoma in cirrhosis: incidence and risk factors", Gastroenterology, 127(5 Suppl 1), pp.S35~S50 (2004)
5. Bruix J, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
6. Song PP, "Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma", World J Gastroenterol, 22, pp.262~274 (2016)
7. Cameron AM, "Screening for viral hepatitis and hepatocellular cancer", Surg Clin North Am, 95, pp.1013~1021 (2015)
8. Phelps ME, "Tomographic measurement of local cerebral glucose metabolic rate in humans with(F-18)2-fluoro-2-deoxy-D-glucose : validation of method", Ann Neurol, 6, pp.371~388 (1979)
9. Gambhir SS, "A tabulated summary of the FDG PET literature", J Nucl Med, 42(5 Suppl), pp.1S~93S (2001)
10. -fluoro-2-deoxy-D-glucose in oncology. Part IIIb: therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma, "J Cancer Res Clin Oncol", 2001, 278~285
11. Iwata Y, "Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors", Ann Nucl Med, 14, pp.121~126 (2000)
12. Khan MA, "Positron emission tomography scanning in the evaluation of hepatocellular carcinoma", J Hepatol, 32, pp.792~797 (2000)
13. Böhm B, "Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors", J Cancer Res Clin Oncol, 130, pp.266~272 (2004)
14. Medina RA, "Glucose transporters: expression, regulation and cancer", Biol Res, 35, pp.9~26 (2002)
15. Amann T, "GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis", Am J Pathol, 174, pp.1544~1552 (2009)
16. Lee M, "18F-Fluorodeoxyglucose uptake on positron emission tomography", computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma, 2017, pp.34, 251~260
17. Hwang SH, "Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET", CT in patients with very early and early hepatocellular carcinoma, 2017, pp.42, 34~39
18. Schug ZT, "The metabolic fate of acetate in cancer", Nat Rev Cancer, 16, pp.708~717 (2016)
19. Ho CL, "11C-acetate PET imaging in hepatocellular carcinoma and other liver masses", J Nucl Med, 44, pp.213~221 (2003)
20. Bjornson E, "Stratification of hepatocellular carcinoma patients based on acetate utilization", Cell Rep, 13, pp.2014~2026 (2015)
21. Jeon J, "Regulation of acetate utilization by monocarboxylate transporter 1(MCT1)in hepatocellular carcinoma(HCC)", Oncol Res, 26, pp.71~81 (2018)
22. Breuhahn K, "Strategies for hepatocellular carcinoma therapy and diagnostics : lessons learned from high throughput and profiling approaches", Hepatology, 53, pp.2112~2121 (2011)
23. Thorgeirsson SS, "Genomic decoding of hepatocellular carcinoma", Gastroenterology, 131, pp.1344~1346 (2006)
24. Wang K, "Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma", Hepatology, 58, pp.706~717 (2013)
25. Kan Z, "Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma", Genome Res, 23, pp.1422~1433 (2013)
26. Totoki Y, "Trans-ancestry mutational landscape of hepatocellular carcinoma genomes", Nat Genet, 46, pp.1267~1273 (2014)
27. Schulze K, "Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets", Nat Genet, 47, pp.505~511 (2015)
28. Fujimoto A, "Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators", Nat Genet, 44, pp.760~764 (2012)
29. Guichard C, "Integrated analysis of somatic mutations and focal copynumber changes identifies key genes and pathways in hepatocellular carcinoma", Nat Genet, 44, pp.694~698 (2012)
30. Huang J, "Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma", Nat Genet, 44, pp.1117~1121 (2012)
31. Cleary SP, "Identification of driver genes in hepatocellular carcinoma by exome sequencing", Hepatology, 58, pp.1693~1702 (2013)
32. Ahn SM, "Genomic portrait of resectable hepatocellular carcinomas : implications of RB1 and FGF19 aberrations for patient stratification", Hepatology, 60, pp.1972~1982 (2014)
33. Nault JC, "TERT promoter mutations in primary liver tumors", Clin Res Hepatol Gastroenterol, 40, pp.9~14 (2016)
34. Jones RG, "Tumor suppressors and cell metabolism : a recipe for cancer growth", Genes Dev, 23, pp.537~548 (2009)
35. Bensaad K, "TIGAR, a p53-inducible regulator of glycolysis and apoptosis", Cell, 126, pp.107~120 (2006)
36. Dang CV, "MYC-induced cancer cell energy metabolism and therapeutic opportunities", Clin Cancer Res, 15, pp.6479~6483 (2009)
37. Shim H, "c-Myc transactivation of LDH-A : implications for tumor metabolism and growth", Proc Natl Acad Sci U S A, 94, pp.6658~6663 (1997)
38. Levine AJ, "The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes", Science, 330, pp.1340~1344 (2010)
39. Méndez-Lucas A, "Glucose catabolism in liver tumors induced by c-MYC can be sustained by various PKM1", PKM2 ratios and pyruvate kinase activities, 2017, pp.77, 4355~4364
40. Semenza GL, "A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation", Mol Cell Biol, 12, pp.5447~5454 (1992)
41. Semenza GL, "Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1", J Biol Chem, 269, pp.23757~23763 (1994)
42. Firth JD, "Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes : similarities with the erythropoietin 3’ enhancer", Proc Natl Acad Sci U S A, 91, pp.6496~6500 (1994)
43. Rigiracciolo DC, "Copper activates HIF-1α", GPER, Oncotarget, pp.2015, 6[DOI]
44. Xia X, "Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis", Proc Natl Acad Sci U S A, 106, pp.4260~4265 (2009)
45. Hamaguchi T, "Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma", Int J Oncol, 33, pp.725~731 (2008)
46. Daskalow K, "Role of hypoxia-inducible transcription factor 1alpha for progression and chemosensitivity of murine hepatocellular carcinoma", J Mol Med(Berl), 88, pp.817~827 (2010)
47. Lau CK, "An Akt", hypoxia-inducible factor-1alpha, Clin Cancer Res, pp.2009, 15[DOI]
48. Krishnamachary B, "Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B", Cancer Res, 66, pp.2725~2731 (2006)
49. Yang MH, "Direct regulation of TWIST by HIF-1alpha promotes metastasis", Nat Cell Biol, 10, pp.295~305 (2008)
50. Zhang L, "Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor-1α in hepatocellular carcinoma", BMC Cancer, 13, pp.108~ (2013)
51. Wang L, "Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma", Hepatol Res, 37, pp.389~396 (2007)
52. Peyrou M, "PTEN in liver diseases and cancer", World J Gastroenterol, 16, pp.4627~4633 (2010)
53. Rahman MA, "Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients : possible relationship with COX II and inducible nitric oxide synthase", Int J Cancer, 100, pp.152~157 (2002)
54. Zundel W, "Loss of PTEN facilitates HIF-1-mediated gene expression", Genes Dev, 14, pp.391~396 (2000)
55. Tian T, "PTEN regulates angiogenesis and VEGF expression through phosphatase dependent and-independent mechanisms in HepG2 cells", Carcinogenesis, 31, pp.1211~1219 (2010)
56. Chen C, "Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia", J Biol Chem, 276, pp.9519~9525 (2001)
57. Sakamoto T, "Targeting the Warburg effect that arises in tumor cells expressing membrane type-1 matrix metalloproteinase", J Biol Chem, 286, pp.14691~14704 (2011)
58. Wang H, "Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K", AKT, Oncotarget, pp.2016, 7[DOI]
59. Wang Y, "MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival", PLoS One, 8, pp.e68744~ (2013)
60. Wang Y, "MicroRNA and cancer--focus on apoptosis", J Cell Mol Med, 13, pp.12~23 (2009)
61. Fornari F, "MiR-221 controls CDKN1C", p57 and CDKN1B, Oncogene, pp.2008, 27[DOI]
62. Lee J, "Controlling SIRT1 expression by microRNAs in health and metabolic disease", Aging(Albany NY), 2, pp.527~534 (2010)
63. Lee J, "A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition", J Biol Chem, 285, pp.12604~12611 (2010)
64. Qin Y, "SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis", Biosci Trends, 7, pp.237~244 (2013)
65. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
66. Aft RL, "Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent : mechanism of cell death", Br J Cancer, 87, pp.805~812 (2002)
67. Zhang Y, "2-DG-regulated RIP and c-FLIP effect on liver cancer cell apoptosis induced by TRAIL", Med Sci Monit, 21, pp.3442~3448 (2015)
68. Tesori V, "The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing", Sci Rep, 5, pp.9149~ (2015)
69. Geschwind JF, "Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma", Expert Rev Anticancer Ther, 4, pp.449~457 (2004)
70. Ko YH, "A translational study"case report"on the small molecule"energy blocker"3-bromopyruvate(3BP)as a potent anticancer agent : from bench side to bedside", J Bioenerg Biomembr, 44, pp.16370~ (2012)
71. Schimmer AD, "Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors", Cancer Res, 66, pp.2367~2375 (2006)
72. Wood TE, "A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death", Mol Cancer Ther, 7, pp.3546~3555 (2008)
73. Liu Y, "A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo", Mol Cancer Ther, 11, pp.1672~1682 (2012)

관련 논문AI추천